![]() ![]() Significant associations were found between EGFR and PI3KCA or CTNNB1 and between KRAS and STK11. NGS identified 693 and 292 mutations in validated and potential oncogenic drivers, respectively. Mutation detection threshold was 2% for 10 ng of DNA input. The R 2 correlation between expected and measured allelic ratio, using commercial samples, was >0.96. TaqMan probes and NGS were compared for their ability to detect EGFR and KRAS mutations, and NGS mutation profiles were analyzed on a large series of non–small-cell lung cancers ( n = 1343). NGS performance was assessed following guidelines. Although NGS was evaluated to screen for theranostic mutations, its usefulness in clinical practice on large series of samples remains to be demonstrated. Theranostic assays are based on single-gene testing, but the ability of next-generation sequencing (NGS) to interrogate numerous genetic alterations will progressively replace single-gene assays. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |